A Recurrent BRCA2 Mutation Explains the Majority of Hereditary Breast and Ovarian Cancer Syndrome Cases in Puerto Rico

被引:18
作者
Diaz-Zabala, Hector J. [1 ]
Ortiz, Ana P. [2 ]
Garland, Lisa [3 ]
Jones, Kristine [3 ]
Perez, Cynthia M. [4 ]
Mora, Edna [5 ,6 ]
Arroyo, Nelly [1 ]
Oleksyk, Taras K. [7 ,8 ]
Echenique, Miguel [9 ]
Matta, Jaime L. [1 ]
Dean, Michael [10 ]
Dutil, Julie [1 ]
机构
[1] Ponce Hlth Sci Univ, Ponce Res Inst, Canc Biol Div, Ponce, PR 00716 USA
[2] Univ Puerto Rico, Comprehens Canc Ctr, Canc Control & Populat Sci Program, San Juan, PR 00936 USA
[3] Leidos Biomed Res Inc, Canc Genom Res Lab, Frederick, MD 21702 USA
[4] Univ Puerto Rico, Grad Sch Publ Hlth, Dept Biostat & Epidemiol, San Juan, PR 00936 USA
[5] Univ Puerto Rico, Sch Med, Dept Surg, San Juan, PR 00936 USA
[6] Univ Puerto Rico, Comprehens Canc Ctr, San Juan, PR 00936 USA
[7] Oakland Univ, Biol Dept, Rochester, MI 48309 USA
[8] Univ Puerto Rico, Dept Biol, Mayaguez, PR 00681 USA
[9] Auxilio Mutuo Hosp, Canc Ctr, San Juan, PR 00936 USA
[10] NCI, Div Canc Epidemiol & Genet, Lab Translat Genom, Gaithersburg, MD 20877 USA
基金
美国国家卫生研究院; 美国国家科学基金会;
关键词
breast cancer genetics; BRCA1/BRCA2; founder effect; Hispanic and Latino populations; SURGICAL ADJUVANT BREAST; RISK-ASSESSMENT; HIGH PROPORTION; BOWEL PROJECT; IDENTIFICATION; PREVALENCE; ANCESTRY; CARRIERS; SUBSTITUTIONS; PERFORMANCE;
D O I
10.3390/cancers10110419
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer is the most common cause of cancer diagnosis in women and is responsible for considerable mortality among the women of Puerto Rico. However, there are few studies in Puerto Rico on the genetic factors influencing risk. To determine the contribution of pathogenic mutations in BRCA1 and BRCA2, we sequenced these genes in 302 cases from two separate medical centers, who were not selected for age of onset or family history. We identified nine cases that are carriers of pathogenic germline mutation. This represents 2.9% of unselected cases and 5.6% of women meeting National Comprehensive Cancer Network (NCCN) criteria for BRCA testing. All of the identified pathogenic mutations were in the BRCA2 gene and the most common mutation is the p.Glu1308Ter (E1308X) mutation in BRCA2 found in eight out of nine cases, representing 89% of the pathogenic carriers. The E1308X mutation has been identified in breast and ovarian cancer families in Spain, and analysis of flanking DNA polymorphisms shows that all E1308X carriers occur on the same haplotype. This is consistent with BRCA2 E1308X being a founder mutation for the Puerto Rican population. These results will contribute to better inform genetic screening and counseling of breast and ovarian cancer cases in Puerto Rico and Puerto Rican populations in mainland United States.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Next-Generation Sequencing of the BRCA1 and BRCA2 Genes for the Genetic Diagnostics of Hereditary Breast and/or Ovarian Cancer
    Trujillano, Daniel
    Weiss, Maximilian E. R.
    Schneider, Juliane
    Koester, Julia
    Papachristos, Efstathios B.
    Saviouk, Viatcheslav
    Zakharkina, Tetyana
    Nahavandi, Nahid
    Kovacevic, Lejla
    Rolfs, Arndt
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (02) : 162 - 170
  • [22] Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations
    Golmard, L.
    Delnatte, C.
    Lauge, A.
    Moncoutier, V.
    Lefol, C.
    Abidallah, K.
    Tenreiro, H.
    Copigny, F.
    Giraudeau, M.
    Guy, C.
    Barbaroux, C.
    Amorim, G.
    Briaux, A.
    Guibert, V.
    Tarabeux, J.
    Caputo, S.
    Collet, A.
    Gesta, P.
    Ingster, O.
    Stern, M-H
    Rouleau, E.
    De Pauw, A.
    Gauthier-Villars, M.
    Buecher, B.
    Bezieau, S.
    Stoppa-Lyonnet, D.
    Houdayer, C.
    ONCOGENE, 2016, 35 (10) : 1324 - 1327
  • [23] Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients
    Fragoso-Ontiveros, Veronica
    Antonio Velazquez-Aragon, Jose
    Maria Nunez-Martinez, Paulina
    de la Luz Mejia-Aguayo, Maria
    Vidal-Millan, Silvia
    Pedroza-Torres, Abraham
    Sanchez-Contreras, Yuliana
    Angel Ramirez-Otero, Miguel
    Muniz-Mendoza, Rodolfo
    Dominguez-Ortiz, Julieta
    Wegman-Ostrosky, Talia
    Enrique Bargallo-Rocha, Juan
    Gallardo-Rincon, Dolores
    Reynoso-Noveron, Nancy
    Arriaga-Canon, Cristian
    Meneses-Garcia, Abelardo
    Alonso Herrera-Montalvo, Luis
    Maria Alvarez-Gomez, Rosa
    PLOS ONE, 2019, 14 (09):
  • [24] Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families
    Riahi, Aouatef
    el Ghourabi, Mohamel
    Fourati, Asma
    Chaabouni-Bouhamed, Habiba
    BREAST CANCER, 2017, 24 (02) : 238 - 244
  • [25] Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers
    Kuchenbaecker, Karoline B.
    McGuffog, Lesley
    Barrowdale, Daniel
    Lee, Andrew
    Soucy, Penny
    Dennis, Joe
    Domchek, Susan M.
    Robson, Mark
    Spurdle, Amanda B.
    Ramus, Susan J.
    Mavaddat, Nasim
    Terry, Mary Beth
    Neuhausen, Susan L.
    Schmutzler, Rita Katharina
    Simard, Jacques
    Pharoah, Paul D. P.
    Offit, Kenneth
    Couch, Fergus J.
    Chenevix-Trench, Georgia
    Easton, Douglas F.
    Antoniou, Antonis C.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (07):
  • [26] Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland
    Wojcik, P.
    Jasiowka, M.
    Strycharz, E.
    Sobol, M.
    Hodorowicz-Zaniewska, D.
    Skotnicki, P.
    Byrski, T.
    Blecharz, P.
    Marczyk, E.
    Cedrych, I.
    Jakubowicz, J.
    Lubinski, J.
    Sopik, V.
    Narod, S.
    Pierzchalski, P.
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2016, 14
  • [27] Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
    Gronwald, Jacek
    Robidoux, Andre
    Kim-Sing, Charmaine
    Tung, Nadine
    Lynch, Henry T.
    Foulkes, William D.
    Manoukian, Siranoush
    Ainsworth, Peter
    Neuhausen, Susan L.
    Demsky, Rochelle
    Eisen, Andrea
    Singer, Christian F.
    Saal, Howard
    Senter, Leigha
    Eng, Charis
    Weitzel, Jeffrey
    Moller, Pal
    Gilchrist, Dawna M.
    Olopade, Olufunmilayo
    Ginsburg, Ophira
    Sun, Ping
    Huzarski, Tomasz
    Lubinski, Jan
    Narod, Steven A.
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 146 (02) : 421 - 427
  • [28] BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients
    Eoh, Kyung Jin
    Park, Ji Soo
    Park, Hyung Seok
    Lee, Seung-Tae
    Han, Jeongwoo
    Lee, Jung-Yun
    Kim, Sang Wun
    Kim, Sunghoon
    Kim, Young Tae
    Nam, Eun Ji
    GYNECOLOGIC ONCOLOGY, 2017, 145 (01) : 137 - 141
  • [29] Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation
    Ribeiro Guerra, Maximiliano
    Coignard, Juliette
    Eon-Marchais, Severine
    Dondon, Marie-Gabrielle
    Le Gal, Dorothee
    Beauvallet, Juana
    Mebirouk, Noura
    Belotti, Muriel
    Caron, Olivier
    Gauthier-Villars, Marion
    Coupier, Isabelle
    Buecher, Bruno
    Lortholary, Alain
    Fricker, Jean-Pierre
    Gesta, Paul
    Nogues, Catherine
    Faivre, Laurence
    Berthet, Pascaline
    Luporsi, Elisabeth
    Delnatte, Capucine
    Bonadona, Valerie
    Maugard, Christine M.
    Pujol, Pascal
    Lasset, Christine
    Longy, Michel
    Bignon, Yves-Jean
    Adenis-Lavignasse, Claude
    Venat-Bouvet, Laurence
    Dreyfus, Helene
    Gladieff, Laurence
    Mortemousque, Isabelle
    Audebert-Bellanger, Severine
    Soubrier, Florent
    Giraud, Sophie
    Lejeune-Dumoulin, Sophie
    Limacher, Jean-Marc
    Chiesa, Jean
    Fajac, Anne
    Floquet, Anne
    Eisinger, Francois
    Tinat, Julie
    Fert-Ferrer, Sandra
    Colas, Chrystelle
    Frebourg, Thierry
    Damiola, Francesca
    Barjhoux, Laure
    Cavaciuti, Eve
    Mazoyer, Sylvie
    Tardivon, Anne
    Lesueur, Fabienne
    BREAST CANCER RESEARCH, 2021, 23 (01)
  • [30] Mutation Patterns in Portuguese Families with Hereditary Breast and Ovarian Cancer Syndrome
    Vicente, Rodrigo
    Costa, Diogo Alpuim
    Vitorino, Marina
    Mendes, Ana Duarte
    Santos, Catarina
    Fontes-Sousa, Mario
    CANCERS, 2022, 14 (19)